Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability

Annals of Neurology

Volumn 71, Issue 5, 2012, Pages 642-652

  Burns, Joshua ^a   Ouvrier, Robert ^a   Estilow, Tim ^b   Shy, Rosemary ^c   Laurá, Matilde ^d,e   Pallant, Julie F ^f   Lek, Monkol ^a   Muntoni, Francesco ^d   Reilly, Mary M ^e   Pareyson, Davide ^g   Acsadi, Gyula ^h   Shy, Michael E ^i,j   Finkel, Richard S ^b,k  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g DEPARTMENT OF NEUROSURGERY   (Italy)

^h Farmington   (United States)

ⁱ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; BODY EQUILIBRIUM; CHARCOT MARIE TOOTH DISEASE PEDIATRIC SCALE; CHILD; CHILDHOOD DISEASE; DISABILITY; ENDURANCE; FEMALE; GAIT; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSATION; STRENGTH; UNITED KINGDOM; VALIDATION STUDY;

CHARCOT-MARIE-TOOTH DISEASE; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; SENSITIVITY AND SPECIFICITY;

EID: 84860173207     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23572     Document Type: Article

References (51)

1. Charcot JM, Marie P,. Sur une forme particulière d'atrophie musculaire progressive, souvent familiale débutant par les pieds et les jambes et atteignant plus tard les mains. Rev Med (Paris) 1886; 6: 97-138.
2. Tooth HH,. The peroneal type of progressive muscular atrophy. London, U.K.: H. K. Lewis, London, 1886.
3. Skre H,. Genetic and clinical aspects of Charcot-Marie-Tooth disease. Clin Genet 1974; 6: 98-118.
4. Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8: 537-544.
5. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8: 1103-1110.
6. Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011; 10: 320-328.
7. Verhamme C, de Haan R, Vermeulen M, et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009; 7: 70.
8. Reilly MM, Shy ME, Muntoni F, et al. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010; 20: 839-846.
9. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008; 70: 378-383.
10. Haberlova J, Seeman P,. Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease. Pediatr Neurol 2010; 43: 407-410.
11. Thomas PK, Marques W Jr, Davis MB, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997; 120: 465-478.
12. Saporta ASD, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69: 22-33.
13. Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68: 849-855.
14. Feely SME, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011; 76: 1690-1696.
15. Niemann A, Berger P, Suter U,. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8: 217-241.
16. Merkies ISJ, Lauria G,. 131st ENMC International workshop: Selection of Outcome Measures for Peripheral Neuropathy Clinical Trials: 10-12 December 2004, Naarden, the Netherlands. Neuromuscul Disord 2006; 16: 149-156.
17. Hobart JC, Cano SJ, Zajicek JP, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007; 6: 1094-1105.
18. van Nes SIM, Vanhoutte EKM, van Doorn PAMDP, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011; 76: 337-345.
19. Mayhew A, Cano S, Scott E, et al. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011; 53: 535-542.
20. Pallant JF, Tennant A,. An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 2007; 46: 1-18.
21. Tabachnick BG, Fidell LS,. In:, Rothman JL, ed. Using multivariate statistics. 5th ed. Boston, MA: Pearson/Allyn & Bacon, 2007:607-675.
22. Kaiser H,. An index of factorial simplicity. Psychometrika 1974; 39: 31-36.
23. Bartlett MS,. Tests of significance in factor analysis. Br J Psychol 1950; 3: 77-85.
24. Cattell RB,. The scree test for the number of factors. Multivariate Behav Res 1966; 1: 245-276.
25. Portney LG, Watkins MP,. In:, Mehalik C, ed. Foundations of clinical research: applications to practice. 2nd ed. Upper Saddle River, NJ: Pearson/Prentice Hal, 2000:557-583.
26. DeVellis RF,. Scale development: theory and applications. 2nd ed. Thousand Oaks, CA: Sage, 2003.
27. Sutton AJ, Muir KR, Jones AC,. Two knees or one person: data analysis strategies for paired joints or organs. Ann Rheum Dis 1997; 56: 401-402.
28. Redmond A, Crane Y, Menz H,. Normative values for the Foot Posture Index. J Foot Ankle Res 2008; 1: 6.
29. Rose KJ, Burns J, North KN,. Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A. J Child Neurol 2010; 25: 463-468.
30. Bennell KL, Khan KM, Matthews BL, et al. Changes in hip and ankle range of motion and hip muscle strength in 8-11 year old novice female ballet dancers and controls: a 12 month follow up study. Br J Sports Med 2001; 35: 54-59.
31. Khan K, Roberts P, Nattrass C, et al. Hip and ankle range of motion in elite classical ballet dancers and controls. Clin J Sport Med 1997; 7: 174-179.
32. Williams C,. Ankle dorsiflexion range of motion in children [PhD dissertation]. Albury, Australia: Charles Sturt University, 2010.
33. Lee-Valkov PM, Aaron DH, Eladoumikdachi F, et al. Measuring normal hand dexterity values in normal 3-, 4-, and 5-year-old children and their relationship with grip and pinch strength. J Hand Ther 2003; 16: 22-28.
34. Poole JL, Burtner PA, Torres TA, et al. Measuring dexterity in children using the Nine-hole Peg Test. J Hand Ther 2005; 18: 348-351.
35. Hager-Ross C, Rosblad B,. Norms for grip strength in children aged 4-16 years. Acta Paediatr 2002; 91: 617-625.
36. Hartman A, van den Bos C, Stijnen T, et al. Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer. Pediatr Blood Cancer 2008; 50: 833-837.
37. Wind AE, Takken T, Helders PJ, et al. Is grip strength a predictor for total muscle strength in healthy children, adolescents, and young adults? Eur J Pediatr 2010; 169: 281-287.
38. Eek MN, Kroksmark AK, Beckung E,. Isometric muscle torque in children 5 to 15 years of age: normative data. Arch Phys Med Rehabil 2006; 87: 1091-1099.
39. Gray K, Gibbons P, Little D, et al. Standardising assessment of recurrent congenital talipes equinovarus (MSc thesis): Sydney, Australia: University of Sydney, 2010.
40. Rose KJ, Burns J, Ryan MM, et al. Reliability of quantifying foot and ankle muscle strength in very young children. Muscle Nerve 2008; 37: 626-631.
41. Yocum A, McCoy SW, Bjornson KF, et al. Reliability and validity of the standing heel-rise test. Phys Occup Ther Pediatr 2010; 30: 190-204.
42. Beenakker EA, van der Hoeven JH, Fock JM, et al. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. Neuromuscul Disord 2001; 11: 441-446.
43. Spink MJ, Fotoohabadi MR, Menz HB,. Foot and ankle strength assessment using hand-held dynamometry: reliability and age-related differences. Gerontology 2009; 3: 3.
44. Castro-Pinero J, Gonzalez-Montesinos JL, Mora J, et al. Percentile values for muscular strength field tests in children aged 6 to 17 years: influence of weight status. J Strength Cond Res 2009: 2295-2310.
45. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. J Pediatr 2007; 150: 395-399.
46. Bruininks RH, Bruininks BD,. Bruininks-Oseretsky test of motor proficiency. 2nd ed. Minneapolis, MN: NCS Pearson, 2005.
47. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score. Neurology 1999; 53: 1660.
48. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005; 64: 1209-1214.
49. Burns J, Ryan MM, Ouvrier RA,. Evolution of foot and ankle manifestations in children with CMT1A. Muscle Nerve 2009; 39: 158-166.
50. Searle RD, Bennett MI, Tennant A,. Can neuropathic screening tools be used as outcome measures? Pain Med 2011; 12: 276-281.
51. Eagle M, Abresch RT, Florence J, et al. Use of a novel system for grading timed function test performance in phase 2b study of ataluren (PTC124(TM)) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Neuromuscul Disord. 2009; 19: 602-602.